Variable

Summary (N = 272)

Age at start of SRT (years)

67 (45 - 85)

Pre-RP PSA (ng/ml)

8.4 (0.0 - 219.0)

Pre-SRT (PSA (ng/ml)

0.6 (0.2 - 21.9)

Pathological tumor stage

T2

136 (50%)

T3a

88 (32%)

T3b

46 (17%)

T4

1 (<1%)

Gleason score

1 - 6

101 (42%)

7

108 (45%)

8 - 10

29 (12%)

Surgical margin

Positive

145 (54%)

Negative

123 (46%)

SRT dose (Gy)

66.6 (54.0 - 72.4)

Visit interval (months) start of SRT to 1^st visit (N = 272)

4.7 (0.7 - 13.8)

1^st to 2^nd visit (N = 118 patients with 2 visits)

3.7 (0.1 - 20.4)

2^nd to 3^rd visit (N = 55 patients with 3 visits)

4.4 (1.0 - 13.3)

3^rd to 4^th visit (N = 33 patients with 4 visits)

4.6 (1.0 - 16.3)

4^rd to 5^th visit (N = 14 patients with 5 visits)

4.6 (1.1 - 12.6)

5^th to 6^th visit (N = 9 patients with 6 visits)

7.2 (1.1 - 11.0)

Start of SRT to lowest PSA measurement (months)

6.3 (1.3 - 79.1)